Skip to content
1. Liga · Regular Season - 12 · Latvia

Mārupe v Smiltene

2-1Full time

Share
Match analysisPre-match brief

Mārupe v Smiltene: the model read

Mārupe meet Smiltene in the 1. Liga regular season - 12. The model makes Mārupe the most likely outcome at 46%, with the full read 46% MĀR, 27% draw, 27% SMI.

The baseline ratings are close, 1512 to 1400, so form and chance quality carry more weight here. Recent form leans Mārupe, 48% against 25%. Attacking output favors Mārupe on expected goals, 1.5 to 1.4 per match.

Across the derived markets, from the same model: both teams to score around 70%, over 2.5 goals around 80%. Draw no bet leans Mārupe at 64%; double chance reads Mārupe or draw 73%, Smiltene or draw 54%.

Mārupe arrive steady: 2W-0D-3L from their last five (6/15 pts), 4 scored and 9 conceded. Recent results: W 2-1 @ Rēzekne FA, L 0-4 v Metta / LU, L 0-1 v Grobiņa, W 2-1 v Smiltene.

Smiltene are patchy: 1W-0D-4L from their last five (3/15 pts), 8 scored and 15 conceded. Recent results: L 3-5 v Rīgas FS II, W 1-0 v Rēzekne FA, L 1-2 @ Mārupe, L 2-4 v Skanste.

Market prices for this fixture have not settled yet. The edge reads as soon as real odds arrive.

MeisterIQ rates the signal 54 of 100. Every input above is on the card; check the work before you trust the number.

Written from the MeisterIQ model output

Pro

The model forecast is a Pro feature.

Live scores, stats and commentary are always free. The glass-box model — probabilities, the edge against the market and the full match dossier — unlocks on Pro.

See plans

Mārupe

LWLLW9-1-10

Scored 1.50 · Conceded 1.50 · Clean sheets 25% · BTTS 45%

  • WARēzekne FA2-1
  • LHMetta / LU0-4
  • LHGrobiņa0-1
  • WHSmiltene2-1
  • LARiga Mariners0-2

Smiltene

LLLWL2-6-12

Scored 1.35 · Conceded 2.55 · Clean sheets 10% · BTTS 65%

  • LHRīgas FS II3-5
  • WHRēzekne FA1-0
  • LAMārupe1-2
  • LHSkanste2-4
  • LHValmiera / BSS1-4

Real data only: recent results, head-to-head and market odds. No model output is shown for teams without Lemeister priors.